CONFIDENTIAL COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • March 29th, 2002 • 3 Dimensional Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
RECITALSCollaborative Research and Development Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances) • England and Wales
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is made the 23rd. day of May, 2011 (“EFFECTIVE DATE”) by and between the LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, a Swiss not-for-profit corporation, with its registered office at Stadelhoferstrasse 22, 8001, Zurich, Switzerland, and having an office at 666 Third Avenue, New York, NY 10017, United States of America (“LICR”) and 4-ANTIBODY AG (“4AB”), incorporated in Switzerland at Schwarzwaldallee 215, CH-4002 Basel, Switzerland.
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • March 9th, 2021 • Longeveron Inc. • Pharmaceutical preparations • Florida
This COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of the 3rd day of March, 2021 (the “Effective Date”) by and between Longeveron, Inc, a corporation organized under the laws of the State of Delaware and having offices at 1951 NW 7th Avenue, Miami, Florida 33136 (“Longeveron”), and University of Miami, a not-for-profit corporation having an office at 1320 S. Dixie Highway, Gables One Tower #650, Locator Code 2960, Coral Gables, FL 33146 (the “Institution”). Each of Longeveron and Institution are sometimes referred to herein as a “Party” or, jointly, as the “Parties.”
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • October 2nd, 2019 • AVRA Medical Robotics, Inc. • Surgical & medical instruments & apparatus • Florida
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of this 10th day of September (the “Effective Date”), by and between INFINITE MIND LLC (“IM”), a Florida limited liability company having a place of business at 3259 Progress Drive, Suite 107, Orlando, Florida 32826 and AVRA MEDICAL ROBOTICS, INC. (“AVRA”), a Florida corporation having a place of business at 3259 Progress Drive, Suite 114, Orlando, Florida 32826
INIHIBIKASE THERAPEUTICS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with an effective date as of the 29th day of February 2012, by and among, on the one hand, Inhibikase Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway, Suite 1927, Atlanta, Georgia (the “Company”) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and Sphaera Pharma Pvt. Ltd., Plot No. 32, Sector 5, IMT Manesar Haryana 122051, India (“Sphaera India”)(together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”). (Company and Sphaera Pharma shall be referred to individually as a “Party” and collectively as the “Parties.”)
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • July 8th, 2021
Please see the attached document prepared pursuant to Article 16.1 of COLLABORATIVE RESEARCH AGREEMENT (20XX) for determined amounts of EXPERIMENT EXPENDITURE.
iNHiBIKASE THERAPEUTICS FIRST AMENDMENT TO COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • July 23rd, 2020 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with an effective date as of the 5th day of October 2012 (the “Amendment Effective Date”) by and among, on the one hand, Inhibikase Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway, Suite 1927, Atlanta, Georgia (the “Company”) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and Sphaera Phanna Pvt. Ltd., with its registered office at E-375, First Floor, Greater Kailash-II, New Delhi-110048, INDIA (“Sphaera India”)(together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”). (Company and Sphaera Pharma shall be referred to individually as a “Party” and collectively as the “Parties.”) Except as otherwise provided in this Agreement, capitalized terms and phrases
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • January 10th, 2007 • Arizona
This Collaborative Research and Development Agreement, hereinafter referred to as the “Agreement,” consists of this Cover Page, an attached Agreement, and various Appendices referenced in the Agreement. This Cover Page serves to identify the Parties to this Agreement:
